- Home
- CYCC vs CTMX Comparison
CYCC vs CTMX Comparison
Compare CYCC & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCC
- CTMX
- Stock Information
- Founded
- CYCC 1992
- CTMX 2008
- Country
- CYCC Malaysia
- CTMX United States
- Employees
- CYCC N/A
- CTMX N/A
- Industry
- CYCC Biotechnology: Pharmaceutical Preparations
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- CYCC Health Care
- CTMX Health Care
- Exchange
- CYCC Nasdaq
- CTMX Nasdaq
- Market Cap
- CYCC 61.2M
- CTMX 60.7M
- IPO Year
- CYCC N/A
- CTMX 2015
- Fundamental
- Price
- CYCC $1.63
- CTMX $2.65
- Analyst Decision
- CYCC
- CTMX Strong Buy
- Analyst Count
- CYCC 0
- CTMX 2
- Target Price
- CYCC N/A
- CTMX $5.00
- AVG Volume (30 Days)
- CYCC 191.0K
- CTMX 11.5M
- Earning Date
- CYCC 05-15-2025
- CTMX 05-12-2025
- Dividend Yield
- CYCC 147.24%
- CTMX N/A
- EPS Growth
- CYCC N/A
- CTMX 128.27
- EPS
- CYCC N/A
- CTMX 0.49
- Revenue
- CYCC $14,000.00
- CTMX $147,557,000.00
- Revenue This Year
- CYCC $137.21
- CTMX N/A
- Revenue Next Year
- CYCC N/A
- CTMX N/A
- P/E Ratio
- CYCC N/A
- CTMX $5.46
- Revenue Growth
- CYCC N/A
- CTMX 23.81
- 52 Week Low
- CYCC $1.36
- CTMX $0.40
- 52 Week High
- CYCC $49.34
- CTMX $2.71
- Technical
- Relative Strength Index (RSI)
- CYCC 32.89
- CTMX 75.39
- Support Level
- CYCC $1.36
- CTMX $1.97
- Resistance Level
- CYCC $1.94
- CTMX $2.64
- Average True Range (ATR)
- CYCC 0.43
- CTMX 0.33
- MACD
- CYCC -0.07
- CTMX 0.04
- Stochastic Oscillator
- CYCC 8.31
- CTMX 94.34
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.